This page shows the publications co-authored by Philip Kantoff and Atish Choudhury.
New agents in metastatic prostate cancer. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1403-9.
A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Res. 2017 02 01; 77(3):753-765.
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532.
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb). 2014 Apr; 6(4):388-98.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.